Romiplostim to prevent thrombocytopenia from chemotherapy – pro
There is some published evidence to prevent chemotherapy-induced thrombocytopenia, but no phase III trials and only 1 phase II. The romiplostim injection is used to increase the number of platelets (cells that help the blood to clot) in order to decrease the risk of bleeding in adults who have immune thrombocytopenia. A recent phase II study by Soff et al evaluated the treatment of CIT with romiplostim. Romiplostim is effective in correcting CIT, and maintenance allows for the resumption of chemotherapy without recurrence of CIT in most patients. Several other articles were identified with the same conclusion. I found one trial: RECITE: A phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer,
Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. J Clin Oncol. 2019 Nov 1;37(31):2892-2898.
Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014 May;22(5):1217-22.
Demeter J, Ketenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. Pathol Oncol Res. 2011 Mar;17(1):141-3.